Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148083 · ClinicalTrials.gov registry record · Phase 3
Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
A Phase 3 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT00148083: Completed Phase 3 study, sponsored by University of Illinois at Chicago.
NCT00148083 is a Phase 3 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 5 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00148083, a Phase 3 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The hypothesis guiding this study is that Risperdal Consta, by improving verbal memory, will improve the ability to benefit from skills training interventions among schizophrenia patients. The primary objective of this study is to compare patients on Risperdal Consta to patients on other atypical antipsychotic medications in terms of their ability to benefit from skills training interventions. A secondary objective of this study is to determine whether patients taking Risperdal Consta improve in other areas of cognitive functioning and social functioning.
Interventions
- BEHAVIORAL Social Skills Training
- DRUG Risperdal Consta (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
What the finished NCT00148083 record still lists
NCT00148083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Social Skills Training is the first listed.
NCT00148083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00148083 about?
NCT00148083 is a clinical study titled "Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia". The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The hypothesis guiding this study is that Risperdal Consta, by improving verbal memory, will improve the...
What is the current status of trial NCT00148083?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2005-09. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00148083?
The interventions under investigation include: Social Skills Training (BEHAVIORAL), Risperdal Consta (drug) (DRUG).
Who is sponsoring clinical trial NCT00148083?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00148083's enrollment target sits among peer trials
5 1997th of 2000 higher than 3 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia